Mezavant Xl

Mesalazine, the active ingredient in Mezavant XL, is a 5‑aminosalicylic acid (5‑ASA) derivative presented as an extended‑release tablet for oral use. It is indicated for the induction and maintenance of remission in ulcerative colitis, targeting inflammation of the colon in adult patients.

GNH USA supplies Mezavant XL as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and timely global delivery.

Mezavant XL, a 5‑ASA derivative, is used in the management of inflammatory bowel disease, specifically ulcerative colitis.

- Ulcerative colitis (induction): achieves remission of active disease. - Ulcerative colitis (maintenance): helps sustain remission over time. - Proctosigmoiditis: controls localized colonic inflammation.

Adverse reactions may occur with mesalazine therapy.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient discomfort. - Abdominal pain: cramping sensations. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Myocarditis: inflammation of the heart muscle. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions.

- Renal function monitoring: assess baseline and periodic kidney function. - Hepatic function monitoring: check liver enzymes regularly. - Hypersensitivity assessment: avoid use in patients with known salicylate allergy. - Cardiovascular caution: use carefully in patients with existing heart disease. - Concomitant drug review: evaluate potential interactions with anticoagulants and methotrexate. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mesalazine may interact with several medicines; awareness of the level of interaction is essential.

Major Interactions (Avoid):